Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 468

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 468
---
,077 |    |

(a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued

operation.

(b) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on

divestments of assets arising from reorganization decisions made by Sano fi .

| SANOFIFORM 20-F2024 | F-91 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Restructuring costs and similar items were € 366 million higher in 2024 than 2023 . For 2024 , they mainly comprise costs relating to severance plans announced by Sanofi. For 2023 , they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs and similar items also include the effects of Sanofi's ongoing transformation projects. D.28. Other gains and losses, and litigation Other gains and losses, and litigation for 2024 represent a charge of € 470 millio n, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see Note D.22.) For 2023 , this line item represented a charge of € 196 million related to major litigation. For 2022 , this line item represented a charge of € 143 million , comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note D.1.3.) and costs related to major litigation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. D.29. Financial expenses and income

An analysis of Financial expenses and Financial income is set forth below:

| (€ million)                                     |   2024 |   2023 | -a | 2022 | -a |
| Cost of debt(b)                                 |   -599 |   -552 |    | -362 |    |
| Interest income(c)                              |    413 |    527 |    |  239 |    |
| Cost of net debt                                |   -186 |    -25 |    | -123 |    |
| Non-operating foreign exchange gains/(losses)   |      6 |     -2 |    |   -3 |